advertisement
Abstract #19141 Published in IGR 3-1
Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide
Halpern MT; Sorensen S; Covert D; Hutton JJournal of Medical Economics 2000; 3: 111-120
The authors analyzed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a health care plan at least two months before and six months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at one, two, and six months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall six-month treatment failure rates were 49.1% and 53.2% for brinzolamide and dorzolamide, respectively. Six-month failure rates due to discontinuing CAI only were 20.9% for brinzolamide and 24.6% for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p = 0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.
Dr J. Hutton, MEDTAP International, 27 Gilbert Street, London W1K 5HQ, UK
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
